#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 13

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Small cell lung cancer recurrent

Recruiting

Registered drugNo placebo

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:GSK5764227

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Desmoid tumour

Recruiting

InvestigationalNo placebo

Study of Nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

InvestigationalNo placebo

Spain

Participants:18–64 years
Substances:Nirogacestat Hydrobromide

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cytarabine

Contact Research Centre

Colorectal cancer metastatic+1

Recruiting

Registered drugNo placebo

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Myelodysplastic syndrome

Recruiting

InvestigationalNo placebo

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate

Contact Research Centre

Cardiomyopathy

Recruiting

Investigational

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational

Spain

Participants:18–64 years · 65+ years

Contact Research Centre

Arteriosclerosis

Recruiting

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pelacarsen

Contact Research Centre

Neoplasm malignant

Recruiting

InvestigationalNo placebo

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE

Contact Research Centre

Respiratory syncytial virus infection

Recruiting

Registered drugNo placebo

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.